Evidence map›Paper›PMID 40692788›Full record

ArticleFrontiers in immunology2025

Cross-talk of m

Pan Song, Jinmao Ye, Haiyang Zhang, Yishu Li, Ruizhi Cao, Yang Feng, Lei Zhang, Min Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pan Song *Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Jinmao Ye *Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Haiyang Zhang *Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Yishu LiDepartment of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Ruizhi CaoDepartment of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Yang FengDepartment of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Lei ZhangDepartment of Head, Neck and Pediatric Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Min SunDepartment of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Esophageal cancer (EC) remains a significant clinical challenge, characterized by its aggressive nature and poor prognosis. Current therapeutic strategies, including targeted therapies, have limitations due to the complex interplay between tumor heterogeneity and the tumor microenvironment (TME). However, the specific contributions of N6-methyladenosine (m Methods: Through comprehensive bioinformatics analyses, a detailed examination of m Results: The findings revealed two distinct m Conclusion: This study highlights the critical role of m

Indexed as

AdenosineEsophageal NeoplasmsTumor MicroenvironmentBiomarkers, TumorComputational BiologyGene Expression Regulation, NeoplasticHumansMethylationPrognosisSingle-Cell AnalysisAdenosineBiomarkers, TumorN-methyladenosineesophagus cancerimmune infiltrationimmunotherapym6Aprognosistumor microenvironment

Identifiers

PMID40692788
PMCPMC12277809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.